Adma Biologics (ADMA) Cash from Investing Activities (2011 - 2025)

Adma Biologics' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$276000.0 for Q4 2025.

• Quarterly Cash from Investing Activities rose 89.96% year-over-year to -$276000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$21.9 million (down 155.29% YoY) and the FY2025 annual result came in at -$21.9 million, down 155.29% from the prior year.
• Cash from Investing Activities was -$276000.0 for Q4 2025 at Adma Biologics, up from -$14.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$276000.0 in Q4 2025 and bottomed at -$14.4 million in Q3 2025.
• A 5-year average of -$3.1 million and a median of -$2.7 million in 2021 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 89.96% in 2025, while the deepest fall reached 1208.56% in 2025.
• Adma Biologics' Cash from Investing Activities stood at -$3.7 million in 2021, then slipped by 1.98% to -$3.7 million in 2022, then jumped by 62.46% to -$1.4 million in 2023, then plunged by 95.45% to -$2.8 million in 2024, then jumped by 89.96% to -$276000.0 in 2025.
• Business Quant data shows ADMA's Cash from Investing Activities at -$276000.0 in Q4 2025, -$14.4 million in Q3 2025, and -$2.5 million in Q2 2025.